TURNING POINT THERAPEUTICS I (TPTX) Stock Price, Quote, News and Overview
NASDAQ:TPTX - Nasdaq - US90041T1088 - Common Stock - Currency: USD
TPTX Quote, Performance and Key Statistics
76.01
+0.52 (+0.69%)
The current stock price of TPTX is 76.01 USD. In the past month the price increased by 1.73%. In the past year, price increased by 18.56%.
TPTX Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About TPTX
Company Profile
Turning Point Therapeutics, Inc. is a clinical-stage oncology biopharmaceutical company, which engages in designing and developing next-generation therapies that target genetic drivers of cancer to improve the lives of patients. The company is headquartered in San Diego, California and currently employs 248 full-time employees. The company went IPO on 2019-04-17. The firm is engaged in designing and developing therapies that target genetic drivers of cancer to improve the lives of patients. The company develops a macrocycle platform from which it designs its pipeline of small, compact tyrosine kinase inhibitors (TKIs). The TKIs generated from its drug discovery platform address unmet needs in TKI naive and resistance settings. The Company’s drug candidate, repotrectinib (TPX-0005), is in Phase I/II trial called TRIDENT-1 for the treatment of patients with ROS1+ advanced non-small-cell lung cancer (NSCLC) and patients with NTRK+ or ALK+ advanced solid tumors. Its multi-cohort Phase II registrational portion of TRIDENT-1 is ongoing at sites in North America, Europe and the Asia-Pacific regions. The Company’s pipeline includes multi-targeted kinase inhibitors: TPX-0046 (a novel RET inhibitor), Elzovantinib (TPX-0022) (a novel MET/CSF1R/SRC inhibitor) and TPX-0131.
Company Info
TURNING POINT THERAPEUTICS I
10628 Science Center Drive, Suite 200
San Diego CALIFORNIA 92121 US
CEO: Athena Countouriotis
Employees: 248
Company Website: https://www.tptherapeutics.com/
Phone: 18589265251.0
TURNING POINT THERAPEUTICS I / TPTX FAQ
What is the stock price of TURNING POINT THERAPEUTICS I today?
The current stock price of TPTX is 76.01 USD. The price increased by 0.69% in the last trading session.
What is the ticker symbol for TURNING POINT THERAPEUTICS I stock?
The exchange symbol of TURNING POINT THERAPEUTICS I is TPTX and it is listed on the Nasdaq exchange.
On which exchange is TPTX stock listed?
TPTX stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for TURNING POINT THERAPEUTICS I stock?
15 analysts have analysed TPTX and the average price target is 74.9 USD. This implies a price decrease of -1.46% is expected in the next year compared to the current price of 76.01. Check the TURNING POINT THERAPEUTICS I stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is TURNING POINT THERAPEUTICS I worth?
TURNING POINT THERAPEUTICS I (TPTX) has a market capitalization of 3.78B USD. This makes TPTX a Mid Cap stock.
How many employees does TURNING POINT THERAPEUTICS I have?
TURNING POINT THERAPEUTICS I (TPTX) currently has 248 employees.
What are the support and resistance levels for TURNING POINT THERAPEUTICS I (TPTX) stock?
TURNING POINT THERAPEUTICS I (TPTX) has a support level at 75.3 and a resistance level at 76.02. Check the full technical report for a detailed analysis of TPTX support and resistance levels.
Is TURNING POINT THERAPEUTICS I (TPTX) expected to grow?
The Revenue of TURNING POINT THERAPEUTICS I (TPTX) is expected to decline by -78.46% in the next year. Check the estimates tab for more information on the TPTX EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy TURNING POINT THERAPEUTICS I (TPTX) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of TPTX, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of TPTX, evaluating the profitability, health, valuation and growth aspects
- TURNING POINT THERAPEUTICS I (TPTX) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- TURNING POINT THERAPEUTICS I (TPTX) Sales and EPS estimates to see what analysts future expectations are.
- TURNING POINT THERAPEUTICS I (TPTX) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- TURNING POINT THERAPEUTICS I (TPTX) Insider and Institutional Ownership to learn about the owners and their transactions.
- TURNING POINT THERAPEUTICS I (TPTX) Stock Chart to make your own analysis
- TURNING POINT THERAPEUTICS I (TPTX) Latest news and press-releases to stay up to date.
Does TURNING POINT THERAPEUTICS I (TPTX) stock pay dividends?
TPTX does not pay a dividend.
When does TURNING POINT THERAPEUTICS I (TPTX) report earnings?
TURNING POINT THERAPEUTICS I (TPTX) will report earnings on 2022-11-07.
What is the Price/Earnings (PE) ratio of TURNING POINT THERAPEUTICS I (TPTX)?
TURNING POINT THERAPEUTICS I (TPTX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-4.79).
TPTX Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to TPTX. When comparing the yearly performance of all stocks, TPTX is one of the better performing stocks in the market, outperforming 98.65% of all stocks.
TPTX Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to TPTX. While TPTX has a great health rating, there are worries on its profitability.
TPTX Financial Highlights
Over the last trailing twelve months TPTX reported a non-GAAP Earnings per Share(EPS) of -4.79. The EPS decreased by -56.03% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | -33959.03% | ||
| ROA | -40.59% | ||
| ROE | N/A | ||
| Debt/Equity | 0 |
TPTX Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 72% to TPTX. The Buy consensus is the average rating of analysts ratings from 15 analysts.
For the next year, analysts expect an EPS growth of -43.06% and a revenue growth -78.46% for TPTX